# Daily Report — Thursday, 2026-08-27 — **BOTH BOOKS**

*Agentic account (••••7339, `limited_margin` / `option_level_3`). Written at 15:20 ET / 19:20 UTC by the first run at or after the 14:15 CT report window — on time, in-session, not under the post-close fallback that yesterday's report needed. All quotes stamped 19:19–19:20Z, ~40 minutes before the bell.*
*Two scheduled runs fired this same slot concurrently and both wrote a report. This file is the **union** of the two, not one of them — the second run's additions are marked where they appear. In the one place the runs overlapped, the BAC grade, they reached the **same verdict on entirely different evidence**, which is worth more than either run alone.*

**One-line summary: the desk took its second-ever autonomous equity entry — $500 of LLY at 1189.7553 — and then declined every other signal on a seven-name screen. NVDA's print resolved overnight with a +8% gap that the desk deliberately did not chase, and the reasoning behind that decline is the most useful thing in this report. Options: nothing opened, thirty-one runs, zero forced trades. The book is three positions, all small, none near an exit.**

---

## 1. Positions — what we own and why

| Position | Entry | Mark (19:19Z) | P/L | Status |
|---|---|---|---|---|
| **SPY 2026-11-20 700P** ×1 (hedge) | $7.49 = $749.00 | 5.25 mid = $525.00 | **−$224.00 / −29.9%** | HOLD — insurance, exempt |
| **LLY** 0.420254 sh (swing) | $1,189.7553 = $500.00 | 1,174.40 = $493.53 | **−$6.47 / −1.29%** | HOLD — thesis intact |
| **PNC** 1.825758 sh (swing) | $246.4729 = $450.02 | 243.10 = $443.84 | **−$6.18 / −1.37%** | HOLD — thesis intact |

**SPY 700P — why we own it.** This is the Aug–Oct drawdown insurance Ryan authorized on 2026-08-05: a single-leg long put, ~9.2% out of the money at entry, struck just under the July-low shelf and the rising 200-day so it pays on a genuine trend break rather than a routine dip. It is **not** a directional trade and it is **exempt from every premium backstop** — the −29.9% drawdown is what a 0.13-delta, 85-DTE put does while the market goes up, and it is a non-event by design. The number is printed here so no future run mistakes it for a fired stop. Delta −0.133, theta −$8.41/day, IV 20.3%, 85 DTE. The roll-or-close decision happens at ~21 DTE (~2026-10-30) **with Ryan**, never autonomously.

**LLY — why we bought it today** (full detail in §2). Mega-cap pharma sold off 3.6% yesterday on a pipeline cull that never touched the franchise that is the thesis. Target 1,280.34. No price stop, ever — this is thesis-managed. It drifted a further −1.26% today, which is drift inside the setup, not a thesis event: invalidation is a close back under the 200-day at ~1,057, some 10% lower.

**PNC — why we still own it.** RSI(2) oversold swing from 2026-08-19; earnings beat, dividend raised 18%, 300-branch expansion, JPMorgan PT $269.50. Target 255.50. Nine days in and 1.4% underwater with the thesis unchanged, which under HARD RULE 5 is a hold, not a problem — underwater swings carry no price stop and are culled at the monthly rebalance if the thesis has decayed. This one hasn't.

---

## 2. Actions taken today

**ONE trade, both books: BUY $500 LLY, filled 0.420254 sh @ $1,189.7553, 15:06:51Z, order `6a90528b`, zero fees.** Dollar-based market order, regular hours, per HARD RULE 3. This was the **second autonomous equity entry ever** and the reasoning ran as follows.

- **The signal.** Connors RSI(2) of 5.8 on the committed 15:01Z intraday report — oversold inside a rising 200-day uptrend. Report-sourced, which is the only kind of equity trade the desk may take on its own. Earnings column blank, cross-checked against the calendar: no print inside the hold window.
- **The news gate (HARD RULE 7), which is what actually decided it.** LLY fell 3.61% on 2026-08-26 after discontinuing three pipeline assets — a frontotemporal-dementia gene therapy, a CD19 antibody, and a radioligand — all three explicitly **for lack of efficacy, not safety.** None of them touches the incretin franchise. That distinction is the whole trade: a safety signal would be a franchise question and an automatic skip; an efficacy cull is a company deciding not to spend more on programs that didn't work, and it is a *completed* event with nothing further to come. Meanwhile the core franchise is expanding — orforglipron's US submission is complete in type-2 diabetes, retatrutide's BLA is slated for Q1 2027, and Q2 was a beat-and-raise. BofA *raised* its target to $1,286 from $950 on the news; ~26-analyst consensus sits $1,277–1,303 against our $1,189.76 entry.
- **What held it back from A+.** Q2 was aided by non-recurring US rebate and discount adjustments. That is an H2 growth-*rate* question, not a franchise break — but it is real, and it is why this graded **A-minus** and was sized at $500, the defensive-posture band, rather than the ~$600–795 the per-name cap alone would have allowed. Conviction sets size; the cap is only a ceiling.
- **Gates cleared before the order, in order:** cash floor computed *first* (72.7% equity-book cash, max compliant buy $955 — not binding); per-name cap 12.6% of account; no oil-sector conflict; no earnings flag; throttle 1 of 3; unleveraged buying power checked, no margin extended.
- **One honest correction from mid-session.** The position is fractional (0.42 shares) because a single whole share is $1,190 — 30% of the account, an outright cap breach. An earlier note dismissed the whole-share preference as moot "because this desk places no stops." That was wrong, and the correction matters for how the position gets protected: the whole-share preference exists so **Ryan's** native 15% trail can be set in-app, and HARD RULE 5 says plainly that sub-1-share positions are "monitored, not automatic." The trade is fine on its merits; the protection mechanism is discretionary rather than automatic, and that is now written into the ledger rather than glossed.

**No options were opened or closed.** Zero closing trades today, broker-confirmed: `get_realized_pnl` returns 0 trades and $0.00 realized for 2026-08-27.

---

## 3. Candidates considered and SKIPPED — the educational section

**NVDA, the day's actual event — declined, and this is the decision the day turned on.** NVDA reported after yesterday's bell (EPS $2.22 vs $2.09, a 6.2% beat) and gapped +6.8% at the open, trading +8.1% by mid-afternoon. ATM IV on the 2026-09-25 board crushed **−18.3%** (0.4144 → 0.3386), landing ~4.3 vol points below the entire pre-print band. Three separate reasons not to touch it:

1. **The trend-maturity gate fails outright.** The move already happened, the catalyst is one session old and fully priced, and the tape has been *fading* it all afternoon — NVDA has printed nine consecutive reads below its 230.265 session high. Buying calls here is buying the move that already occurred.
2. **The crush made NVDA *fair*, not cheap.** Post-crush IV against realized reads 0.9457 raw but **1.0656 ex-gap** — and ex-gap is the honest number, because a board that expires before the next print doesn't get to keep that gap. "IV crushed 18%" and "premium is now cheap" are different claims and only the first was true. Tomorrow the raw ratio will read ~15% cheap purely because the gap day enters the trailing window; that will be an artifact, and it is flagged here in advance so no future run buys it.
3. **Breadth was narrow, not risk-on.** NVDA alone accounts for roughly four fifths of QQQ's gain. AMD and MSFT traded *down*. A one-stock tape is not a regime.

**AMAT (RSI2 1.8) — declined, grade C, re-tested three times today rather than inherited.** The deepest oversold print on the screen and the desk still didn't take it, because the print is measuring the wrong thing. AMAT is **−0.46% today while SMH is +2.38%** — a 2.8-point divergence on the single best day the semis have had this month. The news read explains it: China is down to 28% of revenue, the name is priced for perfection after a ~108% run, and the open question is whether it can outgrow LRCX/KLAC/ASML. Non-participation in the exact rally the setup was waiting for is *evidence about the name*, not noise to trade through. Worth noting: RSI2 *deepened* from 2.3 to 1.8 over the session, and that made the case **weaker**, not stronger — the deeper print is the divergence widening.

*A correction inside that verdict, because it was mis-scoped earlier:* this was first read as a semicap-wide split. Six hours of tape disconfirmed that — LRCX went +0.32% → +1.06% and KLAC recovered too, leaving AMAT as the sole material laggard. The veto is **idiosyncratic to AMAT and does not extend to LRCX or KLAC.** A run inheriting "semicap is lagging" would have wrongly blacklisted a whole group.

**BAC (RSI2 9.8) — new to the screen this hour, declined, grade C.** BAC is −1.49% today against XLF −0.66%, so it is lagging its own sector by 0.8 points on a day financials is the only red group in a green tape. Two independent problems: the RSI2 print at 9.8 barely clears the <10 gate, which is the weakest signal on the board and nowhere near the A-grade-only bar the defensive posture requires; and the desk **already owns PNC**, an underwater bank. Adding a second financials name while the first is underwater and the sector is the day's laggard concentrates exactly the wrong way.

*Two further reasons, added by the second run that fired this same slot and graded BAC independently — same verdict, different evidence:*

- **BAC already fired this exact setup six sessions ago and it failed.** RSI2 printed 6.16 on 08-20 and 5.29 on 08-21 — *deeper* than today's 9.8 — bottoming at 61.520 and holding that level twice. The bounce reached only 62.760, **+2.0% off the low**, and was sold. BAC now trades 61.32, a new low beneath that shelf, and is the **only big-four bank making a new low** — JPM, WFC and C all still sit above their own Aug 20–21 lows. A mean-reversion signal that fires, bounces feebly, and then breaks the level that defined it is a weakening pattern, not a fresh one. (Note XLF understates this: roughly a fifth of it is V/MA/Berkshire/insurance, which held. Financials are fine; *banks* de-rated 3.2–5.4% from their August peaks.)
- **An unresolved binary event lands inside the hold window** — see the Warsh keynote in §5. A 1–3 week swing entered today straddles it, the entry has no edge on it, and HARD RULE 5 forbids the stop that could protect the gap.

**To be precise about what was *not* concluded: BAC's thesis is intact, not broken.** Q2 beat with guidance *raised* (NII to the upper end of 6–8%), there are zero sell ratings, and even the low end of the published target range ($62) sits above spot. This is a **setup and timing decline** — which means the name comes back. Re-grade after the Warsh speech, from scratch on post-event numbers.

**XOM (RSI2 2.4) — excluded on Ryan's standing sector steer,** not on the merits. No new oil-energy entries: E&P, services, refiners, integrated majors. Reply to override.

**BKNG (6.9) grade C · AMZN (8.5) grade B · SCHW (8.9) grade B-/C.** All real setups, none of them A-grade, and the Aug–Oct posture is explicitly A-grade-only. A B is a skip while the posture stands.

**TACTICAL options — a session-wide stand-down, written early and held.** No level ever broke with confirmation. The forward trigger left this morning required a *second* test of QQQ's rising 20-day; QQQ spent the afternoon ~3.4 points above that average, so the price half of the trigger was structurally unreachable and no volume work was owed. Checking the cheap half of a trigger first is what makes a redundant run cheap.

**CORE options — no entry, and the honest reason is IV, not ideas.** The NVDA crush did not make *index* premium cheap: QQQ reads 1.1028 ex-gap and SPY 1.1985 ex-gap, both rich. Buying rich index premium because a single name's event resolved is a non-sequitur.

**One thing that should NOT be cited as a reason for anything today: the cash floor.** It sat at 72.7% with $957 of compliant headroom — over $550 above the practical entry minimum. Every decline above was on the merits. Saying "the floor blocked it" when the floor has that much room is the kind of pass-for-the-wrong-reason that makes a log useless later.

---

## 4. Sleeve state

| | |
|---|---|
| Account value | **$3,970.06** = equity $937.80 / options $525.00 / cash $2,507.26 |
| Unleveraged buying power | **$2,507.26** — equals `buying_power`, so **no margin extended** |
| Deployable after $250 reserve | $2,257.26 |
| Options premium at risk | **$749.00**, all of it the exempt hedge |
| Open option slots | **5 of 5 free** (2 TACTICAL / 3 CORE; hedge excluded) |
| Realized options P/L today | **$0.00** vs the −$400 cap — broker-confirmed, 0 closing trades |
| Options entries used | **0 of 8** |
| Equity entries used | **1 of 3** (LLY) |
| Equity-book cash floor | **72.78%** vs the ≥45% requirement — max compliant buy $956.98 |
| Positions near an exit trigger | **None.** |

Nothing in either book is close to a level. LLY needs +9.0% to its 1,280.34 target and −11% to its invalidation; PNC needs +5.1% to 255.50; the hedge has 85 days and no backstop.

---

## 5. Tomorrow's watchpoints

- **⚠️ Fed Chair Warsh delivers his first Jackson Hole keynote tomorrow, Friday 2026-08-28 at 10:00am ET.** This is the biggest scheduled event in front of the book and it was missing from this report's first draft. Two things make it bank-specific rather than generic macro: Warsh arrives from a hawkish trajectory (his debut FOMC held at 3.50–3.75%, but 9 of 18 dots projected at least one 2026 *hike*, the 2026 median dot moved 3.4% → 3.8%, and he eliminated forward guidance), and the symposium's theme this year is *"Financial Innovation: Implications for Payments and Policy"* — the first time it centers on digital payments and stablecoins, which bears directly on bank deposit funding and payments income. **This is why BAC was deferred rather than bought**, and it is worth watching for PNC too. Expect a real move in rates-sensitive names at the Friday open.
- **The NVDA raw IV/RV ratio will read ~15% cheap tomorrow morning and it will be an artifact** — the +6.8% gap day enters the 30-day realized window and inflates the denominator. The ex-gap ratio barely moves (1.066 → ~1.034). Do not buy that number.
- **Whether the NVDA gap holds.** It faded all afternoon and finished well off the session high. A gap that gives back through today's open would be a genuine signal about how much of the beat was already owned; a gap that holds re-opens the semis complex as a hunting ground.
- **AMAT's re-open criteria, unchanged and both still unmet:** it needs to stop diverging from SMH, or the China revenue-mix question needs a visible resolution. A deeper RSI2 print alone does not qualify.
- **LLY** — nothing scheduled. Watch for H2 guidance commentary on the rebate/discount question, the one open negative in the thesis. Green-enough for Ryan's native 15% trail at **$1,399.71**.
- **PNC** — green-enough at **$289.97**; target 255.50.
- **Cadence, flagged for Ryan and only he can fix it:** yesterday's runs stopped dead at 18:15Z, leaving zero coverage through the final 1h45m of the session, which is why yesterday's report fell to the post-close fallback. Today reached the terminal slot and kept firing, so it did not recur — but the trigger redundancy that causes it is configuration, not something a run can repair from the inside.

---

*Written by the scheduled automation under prompt v8. No Ryan approval is claimed, quoted or implied anywhere in this report; the LLY entry was taken under the autonomous equity authority in HARD RULE 6, and every other decision described here was a decline.*
